Bombay Burmah Trading Corporation Ltd, Praj Industries Ltd, 360 ONE WAM Ltd and Dishman Carbogen Amcis Ltd are among the other gainers in the BSE’s ‘A’ group today, 28 June 2024.

Cholamandalam Financial Holdings Ltd leads gainers in ‘A’ group

Dishman Carbogen plunged 12.26% to Rs 114.55 in early trade today after the firm’s Q4 loss widened to Rs 70.72 crore against Rs 44.62 crore in the corresponding quarter of the previous fiscal.

Dishman Carbogen Q4 earnings effect: Shares plunge 12% in early trade, top losers on BSE

The company reported widening of its consolidated loss to Rs 70.72 crore for the quarter ended March.

Dishman Carbogen declines 10% after Q4 loss widens

Dishman Carbogen Amcis announced that its board approved issuance of non-convertible debentures (NCDs) of aggregating up to Rs 100 crore, with a base issue of Rs 50 crore and green shoe option of Rs 50 crore.

Dishman Carbogen board OKs 100-cr NCDs issue

In the smallcap segment, 36 stocks gave double-digit weekly returns. These include popular names such as Olectra Greentech, Kirloskar Oil Engines, Mangalore Chemicals, SeQuent Scientific, Jindal Saw, Usha Martin, Titagarh Wagons, Dishman Carbogen, Jindal Stainless, and South Indian Bank.

Sensex frowned upon bear party, but 36 smallcaps went on joyride last week

Dishman Carbogen Amcis jumped 6.81% to Rs 127.90 after the company said that its board will consider fund raising through issuance of non-convertible debentures (NCDs) on Friday, 10 March 2023.

Dishman Carbogen gains as board to mull fund raising via NCDs

Shares of Dishman Carbogen Amcis zoomed 14 per cent to Rs 124 on the BSE in Tuesday’s intra-day trade on the back of heavy volumes

This beaten down pharma stock has zoomed over 50% in last 11 trading days

Dishman Carbogen Amcis surged 16.32% to Rs 100.15 after the company’s consolidated net profit rose 32.7% to Rs 46.96 crore on 13.8% increase in revenue from operations to Rs 639.79 crore in Q3 December 2022 over Q3 December 2021.

Dishman Carbogen spurts after Q3 PAT rises 33% YoY

The facility will produce sterile injectable drug products

Dishman Carbogen Amcis opens new facility in France

Built on newly acquired land located 7km from an existing CARBOGEN AMCIS site in Riom, the new facility increases product development and manufacturing capacity for liquid and freeze-dried products for pre-clinical and clinical trials as well as small scale commercial use, the company said.

Dishman Carbogen Amcis opens $50 million new facility in France

Board of Dishman Carbogen Amcis approves NCD issuance up to Rs 100 cr

Hasn't fared well - amongst the low performers

Performance

Seems to be overvalued vs the market average

Valuation

Lagging behind the market in financials growth

Growth

Average profitability - not good, not bad

Profitability

The stock is underpriced and is not in the overbought zone

Current price is less than the intrinsic value

Fundamentals

Good time to consider, stock is not in the overbought zone

Technicals

Entry point

The stock has a moderate number of red flags

Promoter pledged holding

Unsolicited messages

Default probability

Red flags

Dishman Carbogen Amicis Limited is an India-based contract research and manufacturing services (CRAMS) company. The Company is engaged in the process of research and development to late-stage clinical and commercial manufacturing